Life-threatening bleeding in four patients with an unusual excessive response to dabigatran: Implications for emergency surgery and resuscitation

Thrombosis and Haemostasis

Volumn 108, Issue 3, 2012, Pages 583-585

  Louët, Agnès Lillo Le ^a   Wolf, Martine ^b   Soufir, Lilia ^c   Galbois, Arnaud ^d,e,f   Dumenil, Anne Sylvie ^b   Offenstadt, Georges ^d,e,g   Samama, Meyer Michel ^h,i  

^a HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^b HÔPITAL ANTOINE BÉCLÈRE   (France)

^c SAINT JOSEPH HOSPITAL   (France)

^d HÔPITAL SAINT ANTOINE   (France)

^e SORBONNE UNIVERSITÉ   (France)

^f CENTRE DE RECHERCHE SAINT ANTOINE   (France)

^g UMR S 707   (France)

^h HÔTEL DIEU   (France)

ⁱ Biomnis Laboratory   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AMIODARONE; DABIGATRAN; ENOXAPARIN; FIBRINOGEN; FLECAINIDE ACETATE; FRESH FROZEN PLASMA; HEMOGLOBIN; HEPARIN; KANOKAD; PROTHROMBIN COMPLEX; RECOMBINANT BLOOD CLOTTING FACTOR 7A; THROMBOCYTE CONCENTRATE; TRANEXAMIC ACID; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ACUTE KIDNEY FAILURE; AGED; ANEMIA; BLEEDING; BLEEDING TENDENCY; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; DIGESTIVE SYSTEM HEMORRHAGE; DYSPNEA; ENDOSCOPY; ERYTHROCYTE TRANSFUSION; FEMALE; HEART ATRIUM FIBRILLATION; HEMATOMA; HEMODIAFILTRATION; HEMOPERITONEUM; HEMORRHAGIC SHOCK; HUMAN; HYPERTENSION; HYPOTENSION; HYPOVOLEMIC SHOCK; ISCHEMIA; KIDNEY FAILURE; LAPAROTOMY; LETTER; LUNG EMBOLISM; MALE; OLIGURIA; PERITONITIS; PRIORITY JOURNAL; TACHYCARDIA; TOTAL HIP PROSTHESIS; TOTAL KNEE REPLACEMENT;

AGED; AGED, 80 AND OVER; ANTITHROMBINS; ARTHROPLASTY, REPLACEMENT; ATRIAL FIBRILLATION; BENZIMIDAZOLES; BETA-ALANINE; BLOOD COAGULATION FACTORS; COLECTOMY; COMBINED MODALITY THERAPY; EMERGENCIES; ERYTHROCYTE TRANSFUSION; FACTOR VIIA; FATAL OUTCOME; FEMALE; HEMOSTATICS; HUMANS; KIDNEY DISEASES; MALE; PLASMA; POSTOPERATIVE HEMORRHAGE; RECOMBINANT PROTEINS; RENAL DIALYSIS; RESUSCITATION; THROMBOPHILIA;

EID: 84865815830     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH12-03-0149     Document Type: Letter

References (18)

1. Freyburger G, Macouillard G, Labrouche S, et al. Coagulation parameters in patients receiving dabigatran etexilate or rivaroxaban: two observational studies in patients undergoing total hip or total knee replacement. Thromb Res 2011; 127: 457-465.
2. Stangier J, Feuring M. Using the HEMOCLOT direct thrombin inhibitor assay to determine plasma concentrations of dabigatran. Blood Coagul Fibrinolysis 2012; 23: 138-143.
3. van Ryn J, Stangier J, Haertter S, et al. Dabigatran etexilate-a novel, reversible, oral direct thrombin inhibitor: Interpretation of coagulation assays and reversal of anticoagulant activity. Thromb Haemost 2010; 29: 103.
4. Eriksson BI, Dahl OE, Rosencher N, et al. and REMODEL Study Group. Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial. Lancet 2007; 370: 949-956. Erratum in: Lancet 2007; 370: 2004.
5. Eriksson BI, Dahl OE, Rosencher N, et al.; REMODEL Study Group. Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial. J Thromb Haemost 2007; 5: 2178-2185.
6. CHMP Assessment report for Pradaxa. Procedure No. EMEA/H/C/829. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/000829/WC500041062.pdf. Accessed November 15, 2011.
7. US FDA Advisory Committee Briefing Document. August 27, 2010. Available at: http://www.fda.gov/downloads/AdvisoryCommittees/Committees-MeetingMaterials/Drugs/CardiovascularandRenalDrugs% 20AdvisoryCommittee/UCM226009.pdf?bcsi%20scan%2033FB12C90BF 1B18A_1. Accessed November 15, 2011.
8. CHMP Assessment report for Pradaxa. Procedure No. EMEA/H/C/000829/X/13/G. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Assessment_Report_-_Variation/human/000829/WC500110875.pdf. Acessed November 15, 2011.
9. Connolly SJ, Ezekowitz MD, Yusuf S, et al.; RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009; 361: 1139-1151.
10. Hankey GJ, Eikelboom JW Dabigatran etexilate: a new oral thrombin inhibitor Circulation 2011; 123: 1436-1450.
11. Safety advisory issued by the Japanese Ministry of Health, Labour and Welfare regarding Pradaxa (dabigatran etexilate). Available at: http://www.psdh.gov.hk/eps/ControlServlet?Function-Name=EPS&FunctionID=NEWS&action_type=SHOW_NEWS&seq=562550&news_i d=14642. Accessed November 15, 2011.
12. Guidelines for management of bleeding with dabigatran-for possible inclusion into local management protocols. Available at: http://www.pharmac. govt.nz/2011/06/13/Dabigatran%20bleeding% 20management.pdf. Accessed January 24, 2012.
13. Food and Drug Administration. Pradaxa (dabigatran etexilate mesylate): Drug safety communication--Safety review of post-market reports of serious bleeding events. December 7, 2011. Available at: http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm282820.htm. Accessed January 24, 2012.
14. Bell S, Nand J, Spriggs D. New antithrombotic drugs for atrial fibrillation: caution is needed. Lancet 2012; 379: e24; author reply e24-25.
15. Legrand M, Mateo J, Aribaud A, et al. The Use of Dabigatran in Elderly patients. Arch Intern Med 2011; 171: 1285-1286.
16. Therapeutic Goods Administration. Safety Advisory. Available at: http://www.tga.gov.au/safety/alerts-medicine-dabigatran-111005.htm. Accessed November 15, 2011.
17. Wann LS, Curtis AB, Ellenbogen KA, et al. 2011 ACCF/AHA/HRS focused update on the management of patients with atrial fibrillation (update on dabigatran): a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. J Am Coll Cardiol 2011; 57: 1330-1337.
18. Eerenberg ES, Kamphuisen PW, Sijpkens MK, et al. Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects. Circulation 2011; 124: 1573-1579.